{'fraction_non_alphanumeric': 0.014705882352941176, 'fraction_numerical': 0.0, 'mean_word_length': 5.366906474820144, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Funding shortages challenge AIDS drug assistance program.


 HIV patients who rely on AIDS Drug Assistance Programs (ADAPs) sometimes have limited access to new medical advances, and sometimes are refused entry into the programs due to insufficient funding. Recent treatment advances have increased the number of people seeking HIV treatment and using ADAPs, which has increased the overall cost of HIV treatment, but has resulted in a decrease in hospitalizations and a decrease in treatment of HIV-associated opportunistic infections. Even with new funds being committed to meet the increasing HIV treatment costs, some ADAPs are still limiting access to their programs. Some advocates are calling these limitations unethical since delaying treatment can have serious consequences. Many patients are also on substandard treatment regimens and therefore may develop drug resistance.
